Rosalba Torrisi

Summary

Affiliation: Istituto Clinico Humanitas
Country: Italy

Publications

  1. doi request reprint Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 10:483-8. 2010
  2. doi request reprint Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 20:34-8. 2011
  3. doi request reprint Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, Milano, Italy
    Breast Cancer Res Treat 126:431-41. 2011
  4. doi request reprint Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features
    Alessandra Balduzzi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 20:197-203. 2009
  5. doi request reprint Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy
    Claudia D'Alessandro
    Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Breast J 14:435-41. 2008
  6. ncbi request reprint Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti, 435 20141, Milan, Italy
    Cancer Chemother Pharmacol 62:667-72. 2008
  7. doi request reprint Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity
    Giuseppe Viale
    Division of Pathology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:317-28. 2009
  8. doi request reprint Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer
    Laura Orlando
    Research Unit Medical Senology, European Institute of Oncology, Milan, Italy
    Breast 17:506-11. 2008
  9. doi request reprint Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors
    Rosalba Torrisi
    Research Unit in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 17:654-60. 2008
  10. doi request reprint Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy
    Marco Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:359-69. 2009

Detail Information

Publications26

  1. doi request reprint Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 10:483-8. 2010
    ..Given its low cardiotoxicity, the combination of PLD and trastuzumab appears most attractive in the treatment of human epidermal factor receptor 2 (HER2)-positive breast cancer...
  2. doi request reprint Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 20:34-8. 2011
    ..To explore the activity of pegylated liposomal doxorubicin (PLD) as neoadjuvant therapy of breast cancer...
  3. doi request reprint Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, Milano, Italy
    Breast Cancer Res Treat 126:431-41. 2011
    ....
  4. doi request reprint Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features
    Alessandra Balduzzi
    Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Anticancer Drugs 20:197-203. 2009
    ..A non-negligible rate of progressive disease was observed, suggesting careful monitoring of the patients. Further studies evaluating the potential benefit of bevacizumab in neoadjuvant treatment need to be tested...
  5. doi request reprint Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy
    Claudia D'Alessandro
    Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Breast J 14:435-41. 2008
    ..91; 95% CI 1.69-20.7; p = 0.005), in particular if HER2/neu overexpression was detected (HR: 16.5; 95% CI 4.24-64.5; p < 0.0001). New multimodality and targeted strategies should be explored in endocrine nonresponsive breast cancer...
  6. ncbi request reprint Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
    Rosalba Torrisi
    Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti, 435 20141, Milan, Italy
    Cancer Chemother Pharmacol 62:667-72. 2008
    ..No specific treatment guidelines are available for triple-negative breast cancers, defined by a lack of expression of estrogen (ER), progesterone (PgR), and HER2 receptors...
  7. doi request reprint Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity
    Giuseppe Viale
    Division of Pathology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:317-28. 2009
    ..EGFR immunoreactivity significantly correlates with worse prognosis in patients with triple-negative IDC, supporting further studies on the correlation between the degree of EGFR expression and outcome of triple negative breast cancer...
  8. doi request reprint Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer
    Laura Orlando
    Research Unit Medical Senology, European Institute of Oncology, Milan, Italy
    Breast 17:506-11. 2008
    ..We analyzed the role of Topo II gene status in the prediction of pathological complete remission (pCR) after primary anthracycline-based chemotherapy in non- endocrine responsive breast cancers overexpressing Her2/neu...
  9. doi request reprint Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors
    Rosalba Torrisi
    Research Unit in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 17:654-60. 2008
    ..Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer...
  10. doi request reprint Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy
    Marco Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 116:359-69. 2009
    ..4, 95% CI 3.5-11.6, for DFS; HR 3.6 95% CI 2.4-5.6 for OS). Response and outcome after PCT are correlated with the degree of expression of steroid hormone receptors. Studies on tailored preoperative therapies are needed...
  11. doi request reprint Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 20:319-23. 2011
    ..To evaluate the role of pegylated liposomal doxorubicin with low-dose metronomic cyclophosphamide as primary systemic treatment in locally advanced breast cancer...
  12. doi request reprint A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer
    Marco Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Eur J Cancer 46:2216-24. 2010
    ..Tools able to predict pathological complete response (pCR) to preoperative chemotherapy might improve treatment outcome...
  13. doi request reprint Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 26:4899-905. 2008
    ..Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. When used in association with targeted antiangiogenic drugs, it was more active than metronomic therapy alone in preclinical and clinical studies...
  14. pmc Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Laura Orlando
    Unit of Research in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    BMC Cancer 6:225. 2006
    ..We therefore tested the activity of the combination of Trastuzumab with metronomic, low dose chemotherapy with cyclophosphamide (CTX) and methotrexate (MTX) in metastatic breast cancer (MBC)...
  15. ncbi request reprint Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer
    Andrea Rocca
    Research Unit in Medical Senology, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Anticancer Res 29:5111-9. 2009
    ..The prognostic role of serum levels of molecular biomarkers during the perioperative period in patients with early breast cancer is not clear...
  16. ncbi request reprint Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment
    Marco Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Clin Cancer Res 10:6622-8. 2004
    ..The purpose of this research was to identify factors predicting response to preoperative chemotherapy...
  17. ncbi request reprint Primary therapy with ECF in combination with a GnRH analog in premenopausal women with hormone receptor-positive T2-T4 breast cancer
    Rosalba Torrisi
    Research Unit of Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 16:73-80. 2007
    ..Further studies combining chemotherapy and endocrine agents are warranted in patients with hormone receptor-positive tumors...
  18. ncbi request reprint HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17
    Rosalba Torrisi
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Eur J Cancer 43:2339-44. 2007
    ..Our results suggest that FISH testing should be considered for tumours with 50% positive stained cells and that polysomy 17 without amplification is not associated with poor prognostic features...
  19. ncbi request reprint Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter
    Giuseppe Curigliano
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Support Care Cancer 15:1213-7. 2007
    ..The aim of this study was to evaluate the efficacy and safety of low-dose aspirin for the prevention of VTE...
  20. ncbi request reprint Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre
    Chiara Catania
    Unit for Medical Care, Division of Medical Oncology, European Institute of Oncology, 20141, Milan, Italy
    Breast Cancer Res Treat 106:97-103. 2007
    ..The drug was administered to heavily pre-treated patients with advanced breast cancer (ABC). Patients received Fulvestrant after disease progression (PD) on a previous endocrine treatment or as maintenance treatment after chemotherapy...
  21. ncbi request reprint Weekly non-pegylated liposomal doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer
    Giovanna Masci
    Oncology and Hematology Unit, Humanitas Cancer Center, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Anticancer Res 33:4603-9. 2013
    ....
  22. ncbi request reprint Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features
    Giuseppe Curigliano
    European Institute of Oncology, Milan, Italy
    Clin Breast Cancer 5:125-30. 2004
    ..The development of more effective therapies for very young women with breast cancer requires tailored treatment investigations and research focused on issues specific to these patients...
  23. ncbi request reprint Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement
    Marco Colleoni
    Division of Medical Oncology, Department of Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy
    J Clin Oncol 23:1379-89. 2005
    ....
  24. doi request reprint Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation
    Daniela Cardinale
    Cardiology Unit, European Institute of Oncology, Milan, Italy
    J Clin Oncol 28:3910-6. 2010
    ..The usefulness of troponin I (TNI) in the identification of patients at risk for TIC and in the prediction of LVEF recovery has never been investigated...
  25. ncbi request reprint A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, and University of Milan School of Medicine, Milan, Italy
    J Natl Cancer Inst 95:779-90. 2003
    ....
  26. pmc Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments
    Marta Scorsetti
    Radiotherapy and Radiosurgery, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Milano, Italy
    Radiat Oncol 7:145. 2012
    ..To report results in terms of feasibility and early toxicity of hypofractionated simultaneous integrated boost (SIB) approach with Volumetric Modulated Arc Therapy (VMAT) as adjuvant treatment after breast-conserving surgery...